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range of tissue-derived and pluripotent stem cell–derived
gastrointestinal (GI) tissues in vitro. These systems,
broadly referred to as organoids, have allowed the ﬁeld to
move away from the often nonphysiological, transformed
cell lines that have been used for decades in GI research.
Organoids are derived from primary tissues and have the
capacity for long-term growth. They contain varying levels
of cellular complexity and physiological similarity to native
organ systems. We review the latest discoveries from
studies of tissue-derived and pluripotent stem cell–derived
intestinal, gastric, esophageal, liver, and pancreatic orga-
noids. These studies have provided important insights into
GI development, tissue homeostasis, and disease and might
be used to develop personalized medicines.Keywords: Gut Organoids; Gastrointestinal Development;
Gastrointestinal Regeneration; Gastrointestinal Disease.
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Open access under CC BY-NC-ND license.Tforegut, midgut, and hindgut, and each region gives
rise to different tissues and organs.1–4 The foregut endo-
derm gives rise to the epithelium of the oral cavity, pharynx,
esophagus, stomach, liver, pancreas, and proximal duo-
denum. The midgut and hindgut endoderm give rise to the
epithelium of the distal duodenum, jejunum, ileum, colon,
rectum, and anal canal, as well as the epithelial lining of the
bladder and urethra.4–36 In vitro organoid cultures are
generated from stem or progenitor cells; they have capa-
bilities for long-term growth, cellular diversity, function, and
spatial organization speciﬁc to the organ they represent, and
they have been used to study endoderm-derived GI
organs.37–54 Although they were initially developed as a way
to culture primary mouse GI tissues, organoid technologies
now enable the growth of diverse primary human tissues
in vitro.43,44,47,50,52,55–60
Before the development of human GI organoids, the GI
tract was modeled using cell lines and explanted tissue, both
of which have signiﬁcant limitations (reviewed by Pageot
et al61). Cell lines, for example, are often derived from ma-
lignant specimens or are immortalized by viral infection, cell
fusion, or introduction of oncogenes, which limit their use indevelopmental, physiological, and regenerative studies.62–67
Explant cultures, which have organotypic properties such as
complex 3-dimensional (3D) architecture and cellular het-
erogeneity, have important roles in studies of development
and physiology but are limited by their short-term
nature.53,68–75 Recent advances in maintaining GI tissues
in long-term in vitro cultures have allowed researchers to
overcome many of these barriers, invigorating basic and
translational research.37–52,54 For example, long-term orga-
noid cultures have been used to examine the stem cell niche,
cellular differentiation, interactions between cells, and
physiological functions.37,38,40–42,44,46–51,54,57,58,60,76–85 They
have also been used to model malignancy, infection, and
inﬂammation, as well as in toxicology studies.
Many research articles and reviews have highlighted
the use of organoid systems to characterize the adult
stem cell niche and gut morphogenesis and will not be
covered in detail in this review but are discussed else-
where.1,3,40–43,56,58,59,70,86–95 We aim to deﬁne and discuss
the variety of long-term in vitro GI models that have been
created and how they have increased our understanding of
development, genetic diseases of the GI tract, malignancy,
host-pathogen interactions, tissue reprogramming, and
regeneration.
Deﬁning Organotypic GI Culture Models
The term “organotypic” has referred to tissue explanted
from an organ that continues to function as it would
in vivo.71,96,97 However, with recent advances in de novo
differentiation of 3D organ-like tissues from human
pluripotent stem cells, and in long-term culture of human
Figure 1. Composition,
cellular sources, and
nomenclature for GI orga-
notypic culture systems.
GI organotypic cultures
consist of short-term
explant cultures and long-
term organoid cultures.
The 3 types of GI organoid
cultures include (1) tissue-
derived epithelial, (2)
tissue-derived epithelial-
mesenchymal, and (3)
PSC-derived organoids.
Tissue-derived epithelium
and PSC-derived intestinal
organoids are shown as
examples of each type of
tissue.
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expanded.98 We use the term “organotypic” to deﬁne
short-term explant models and long-term in vitro culture
systems that recapitulate the complex cellular diversity and
function of the native organ. Long-term organotypic
culture systems include primary (tissue-derived)
epithelium-only organoids,37,38,40–42,44,45,49,51,54,60,70 tissue-
derived epithelial-mesenchymal organoids,46,48,70,99 and
pluripotent stem cell (PSC)-derived organoids47,50,80,100,101
(see Figure 1).
The ability to grow long-term intestinal organotypic
cultures in vitro was made possible through identiﬁcation of
conditions that mimic the intestinal stem cell niche.48,49 In
2009, Sato et al isolated intestinal crypts from mice that
gave rise to epithelium-only organoids when cultured with
laminin-rich Matrigel (BD Biosciences, San Jose, CA) and
growth factors, which reﬂected the intestinal niche in vivo.49
These epithelial organoids could be generated from a single
intestinal stem cell, identiﬁed by LGR5 expression.49 Using
another strategy, Ootani et al generated epithelium-
mesenchyme organoids by culturing minced fragments ofsmall intestine or colon in a collagen matrix exposed to an
air-liquid interface. These fragments gave rise to highly
proliferative epithelium, with supportive myoﬁbroblasts
located along the basolateral aspect of the epithelial cells.
The resulting epithelial-mesenchymal organoids could be
maintained in vitro for up to 1 year.48 For long-term growth,
both types of intestinal organoids required media contain-
ing growth factors that stimulate Wnt signaling; this re-
capitulates the in vivo environment of the intestinal crypt,
which contains high levels of Wnt signaling.
These achievements laid the groundwork for studies
describing differentiation and growth of human embryonic
and induced PSC (ESC and iPSC)-derived organo-
ids.47,50,80,100,101 In these studies, ESCs or iPSCs were
differentiated into intestine or gastric tissue using stepwise
differentiation that mimicked stages of embryonic devel-
opment (reviewed by Sinagoga and Wells1 and Wells and
Spence3). This culture system, similar to culture of tissue-
derived epithelial and epithelial-mesenchymal organoids,
required a 3D extracellular matrix with media that sup-
ported high levels of Wnt signaling.
Figure 2.GI organ diversity represented in organoid systems. GI organoids have been generated from esophagus, liver, biliary
tree, stomach, pancreas, small intestine, and large intestine. GI tract schematic modiﬁed from Zorn and Wells with
permission.4
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Wnt signaling, have more recently enabled the culture of
primary human esophageal, gastric, liver, pancreatic, and
colon organoids (see Figure 2).37,38,44,60 We brieﬂy discuss
advances in pancreas and liver organoids but will focus on
the implantation of PSC-derived and tissue-derived epithe-
lial esophageal, gastric, and intestinal organoids for studies
of development, disease, and regenerative medicine.Pancreas and Liver
The distal foregut gives rise to organ buds that form the
liver and the dorsal and ventral pancreas. During develop-
ment, the hepatoblast gives rise to ductal epithelium and
hepatocytes (reviewed by Miyajima et al102). In adults,
however, the process by which regeneration occurs after
liver damage is complex. Hepatocytes are believed to be the
primary contributors to regeneration; however, a bipotent
progenitor in the ductal epithelium89,103 has also been re-
ported to give rise to hepatocytes and ducts. Interestingly,
murine bipotent progenitors also generate epithelial liver
organoids, which can be differentiated towards duct or he-
patocyte depending on culture conditions in vitro.42,43,89
Organoids differentiated towards hepatocytes are func-
tional in vitro and in a mouse model of liver disease.
However, cholangiocyte function after differentiation to-
wards ductal tissue remains to be seen.
In addition to tissue-derived liver organoids, human
PSC-derived liver buds have recently been described. These
were generated by combining human iPSC-derivedhepatoblasts104 with human umbilical endothelial vein
cells and human mesenchymal stem cells to develop self-
organizing 3D tissues.52 Transplantation of the liver buds
into mice resulted in vascularization and maturation of the
tissue. Furthermore, transplanted liver buds were capable of
rescuing drug-induced liver failure. Similar to tissue-derived
epithelial liver organoids, however, these liver buds did not
generate functional ductal epithelium. More recently, ESCs
and iPSCs have been used to generate functional ductal
epithelium characterized by bile acid transfer, cystic ﬁbrosis
transmembrane conductance regulator (CFTR)-mediated
ﬂuid secretion, and responses to the hormones secretin and
somatostatin.58,59 It will be interesting to determine if
inclusion of PSC-derived cholangiocyte organoids in PSC-
derived liver buds results in organization of functional
hepatocyte and ductal structures.
Similar to liver epithelial organoids, pancreatic epithelial
organoids can be generated from embryonic progenitors
or adult progenitors that arise after injury.41 Pancreatic
duct ligation in mice results in Wnt activity and the devel-
opment of LGR5þ progenitors in the pancreatic ductal
epithelium, which can generate pancreatic epithelial orga-
noids. Pancreatic organoids reaggregated with embryonic
pancreas primarily expressed ductal markers in vitro and on
transplantation. However, 5% of reaggregated transplanted
organoids gave rise to monohormonal insulin-, glucagon-,
and somatostatin-producing endocrine lineages. On the
other hand, pancreatic epithelial organoids generated from
mouse embryonic tissue can give rise to acinar and endo-
crine structures in vitro.40 These ﬁndings provide evidence
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ated from adult pancreatic progenitors compared with
organoids derived from embryonic pancreatic progenitors.
Human epithelial pancreatic organoids have also been
generated from pancreatic ductal cells. Although organoids
from adult progenitors are important in the study of
pancreatic ductal adenocarcinoma, these organoids require
ectopic expression of PDX1, MAFA, and neurogenin-3
(NEUROG3 or PMN) for differentiation into insulin-
producing cells. Further studies are required to elucidate
conditions for endocrine differentiation of human pancre-
atic organoids in the absence of genetic modiﬁcation.56,105Development
Although mouse models and genetic analyses have
greatly increased our understanding of embryonic GI
development, mouse development does not always reca-
pitulate human development, particularly in development of
the intestinal stem cell niche.106–111 For example, Paneth
cells, which contribute to maintenance of the adult stem cell
niche,112 develop in the ﬁrst trimester of human gestation.
However, Paneth cells do not differentiate until postnatal
day 14 in mice.106,107 Furthermore, epidermal growth factor
increases intestinal epithelial maturation in mice but de-
creases maturation of human fetal intestine in vitro.108–111
GI organoids generated from human specimens are there-
fore a valuable adjunct to mouse developmental studies and
can be used to study developmental events that are difﬁcult
to study in vivo.
Small intestine epithelial organoids generated from fetal
mice have been used to study the fetal intestinal niche.57,81
In contrast to adult epithelial organoids, which demonstrate
budding morphology, fetal epithelial organoids frequently
formed spherical organoids or spheroids. This tendency to
form spheroids, however, decreased with age, such that
intestine from postnatal day 15 mice did not generate
spheroids.81 Interestingly, messenger RNA expression of
several important intestinal genes differed markedly
between fetal spherical and budding organoids, such that
fetal budding organoids more closely resembled adult
budding organoids.81
In a separate study, exogenous Wnt ligand increased
maturation of fetal spheroids into budding organoids.57
Epithelial spheroids generated from human fetal small
intestine and PSC-derived human intestinal organoids were
more closely related to immature mouse fetal spheroids
than to adult tissue.57 These studies exploited the fetal state
captured by the intestinal organoid culture system to show
that Wnt signaling stimulates a transition of the fetal orga-
noids grown in vitro from spheroid to budding structure.
Furthermore, mouse fetal spheroids that readily engrafted
into areas of colitis, induced by dextran sodium sulfate
(DSS), appeared to adopt a colonic fate, indicated by
expression of the colonic enzyme carbonic anhydrase II and
lack of expression of small intestine enzymes such as lyso-
zyme and alkaline phosphatase.57 These data indicate that
mouse fetal small intestine spheroids, in contrast to adult
organoids,113 appear to retain plasticity reﬂecting theirimmature status. It is unclear if human fetal intestinal
spheroids possess similar cellular plasticity.
Like primary human fetal tissue, human PSC-derived
tissues are better suited to developmental studies rather
than the study of adult processes due to their fetal resem-
blance. For example, hepatocytes or liver organoids gener-
ated from PSCs were more closely related to early fetal liver
rather than adult liver, based on expression of important
regulators of liver development.52,104,114 Similarly, the
maturational status of early iterations of PSC-derived insu-
lin-producing cells represented fetal pancreatic beta cells,
based on their transcriptional proﬁle and lack of response to
glucose.115
The transcriptome of PSC-derived gastric and lung
organoids more closely resembles that of fetal compared
with adult lung.47,116 In addition, RNA sequence-based
transcriptional proﬁling conﬁrmed that human PSC-
derived small intestine organoids are most similar to fetal
tissue.82 This study showed that features of human fetal to
adult maturation included increased expression of the
intestinal stem cell marker OLFM4, as well as increased
Paneth cell differentiation and expression of brush border
enzymes on enterocytes. Transplantation of PSC-derived
organoids into immunocompromised mice resulted in the
maturation of these fetal-like tissues into tissues resembling
those of adults. This maturation was characterized by
prominent crypt-villus structures, increased expression of
OLFM4, brush border enzymes, and other markers of mature
small intestine such as dipeptidyl peptidase 4, glucose
transporter type 2, and villin.82,117
Given the diverse array of in vitro grown human tissues
(primary or PSC-derived, fetal or adult, epithelium only, or
epithelium plus mesenchyme), it will be important to
consider the experimental strengths and limitations of each
system when designing experiments and implementing such
systems. For example, tissue-derived epithelial intestinal
organoids can be generated in less than 2 weeks, whereas
PSC-derived intestinal organoids require 5 weeks. Fetal
epithelial spheroids generated from early intestine progress
into budding organoids with low efﬁciency, whereas fetal
epithelial spheroids from perinatal tissue progress to
budding organoids with high efﬁciency.57,81 Furthermore,
mouse epithelial organoids require induction of inﬂamma-
tion for transplantation, whereas human epithelial organoids
have not been successfully transplanted. Fetal epithelial
spheroids might therefore be best suited for in vitro physio-
logical studies that characterize the early fetal intestine. In
contrast, PSC-derived intestinal organoids undergo matura-
tion with high efﬁciency when transplanted in vivo and are
therefore amenable to in vivo studies of human development.Models of GI Disease
GI organoids have been used to model human genetic
diseases, infections, inﬂammatory bowel diseases (IBD), and
malignancies. Because of our ability to grow robust and
diverse patient-derived organoids, we can use these tissues
to conduct drug screens and identify personalized
approaches for treating disease.
1102 Dedhia et al Gastroenterology Vol. 150, No. 5
REVIEW
S
AND
PERSPECTIVESMonogenic Diseases That Affect the Epithelium
Epithelial organoids have been used to assess function of
the CFTR; mutations in this transporter can cause cystic
ﬁbrosis (CF).78,118 CFTR mutations result in accumulation of
thick secretions in both the pulmonary and GI tracts.
Dekkers et al identiﬁed forskolin-induced swelling of
normal epithelial intestinal organoids as a physiological
function of nonmutant CFTR. Strikingly, epithelial organoids
generated primarily from patients with CF did not undergo
forskolin-induced swelling.78 However, forskolin-induced
swelling was restored in patient-derived organoids upon
incubation with pharmacological agents that improved
function of the CFTR. Furthermore, correction of CFTR
mutations in epithelial organoids from the small intestine of
patients with CF, using the CRISPR/Cas9 genome editing
system, improved forskolin-induced swelling.118 Epithelial
organoid cultures can therefore model disease physiology,
and genome editing can be used to repair genetic mutations
in organoids.
GI epithelial organoids have also been used to study
microvillus inclusion disease (MVID) and multiple intestinal
atresia (MIA).119,120 MVID is frequently caused by mutations
in myosin Vb (MYO5B) that result in inappropriate locali-
zation of apical proteins and enterocyte polarization.121,122
Wiegerinck et al identiﬁed a mutation in syntaxin 3
(STX3) by whole-exome sequencing in patients with MVID
but who did not have a mutation in MYO5B. Duodenal
epithelial enteroids from these patients had partial loss of
microvilli, inappropriate accumulation of vesicles, and
absence of STX3 protein.120 Patients with MIA can develop
atresia from the stomach to the rectum.123 Using a combi-
nation of genome-wide linkage analysis and whole-exome
sequencing, Bigorgne et al and Avitzur et al identiﬁed pre-
viously uncharacterized mutations in the tetratricopeptide
repeat domain 7A (TTC7A) of patients with MIA and com-
bined immunodeﬁciency. Intestinal epithelial organoids
generated from a subset of these patients showed disturbed
polarity and disrupted epithelial architecture.119,124 Epithe-
lial organoids generated from patient specimens can there-
fore model and increase our understanding of numerous
genetic diseases of the GI tract. Epithelial organoids could be
of particular use in helping us identify the GI component of
complex genetic diseases that affect multiple organ systems.
Enteric anendocrinosis is an extremely rare disease
caused by mutations in NEUROG3 that is characterized by
severe malabsorptive diarrhea and a lack of intestinal
enteroendocrine cells.125,126 PSC-derived intestinal organo-
ids with adenoviral knockdown of NEUROG3 have fewer
enteroendocrine cells, similar to patients with anendocri-
nosis.50 McGrath et al recently deleted NEUROG3 in ESCs,
which resulted in failure to formmature pancreatic endocrine
cells.127 We anticipate the PSC-derived human intestinal
organoids from these ESCs will similarly be devoid of enter-
oendocrine cells, although additional studies are required.Inﬂammatory Bowel Disease
IBD is characterized by mucosal inﬂammation of the GI
tract that is caused by a combination of geneticsusceptibility, immune dysregulation, disruptions in the
microbial communities, and environmental factors.128
Organoid cultures have not yet been used to directly
model IBD but have been used to study cell death,
mucosal integrity, and the effects of inﬂammatory
cytokines.118,129–131 For example, IBD specimens were
found to contain foci of hypoxic inﬂammation,132 and levels
of hypoxia inducible factor 2a (HIF2A or EPAS) were
increased in the intestinal epithelial cells from mice with
colitis and patients with IBD.130 Disruption of Hif2a in mice
reduced features of colitis induced by DSS. Intestinal
epithelial cells from the HIF2A-null mice expressed lower
levels of inﬂammatory cytokines, including tumor necrosis
factor, following DSS induction of colitis, compared with
mice that express HIF2A. Similarly, under hypoxic condi-
tions, PSC-derived intestinal organoids increased expression
of tumor necrosis factor.130
Abnormal Paneth cell phenotypes are associated with
speciﬁc susceptibility alleles for Crohn’s disease.134
Administration of interferon gamma, an inﬂammatory
cytokine, to cultures of mouse small intestinal organoids
caused Paneth cell degranulation, which was associated
with apoptosis.135 In the healthy intestine, Paneth cells are
quickly replaced. However, continuous exposure to inter-
feron gamma causes progressive loss of Paneth cells, which
could contribute to development of IBD.135 Further studies,
potentially with epithelial organoids from patients with IBD,
are necessary to determine if Paneth cell degranulation is
involved in the pathogenesis of IBD. IBD can also lead to
ﬁbrosis in the intestine, and PSC-derived organoids have
been used to model a ﬁbrosis-like response to Tgfb stimu-
lation that could be reversed using anti-ﬁbrotic drugs.133
IBD is associated with increased risk of colorectal can-
cer. Oxidative stress could be involved in the pathogenesis
of IBD and/or IBD-associated cancer. For example, deletion
of the antioxidant, selenoprotein P, exacerbated DSS-
induced colitis and tumorigenesis.136 Small intestine
epithelial organoids generated from these mice had
increased baseline proliferation but decreased survival
when exposed to the oxidative stressor hydrogen
peroxide.136 It will be interesting to determine if this par-
adoxical relationship also occurs in epithelial organoids
generated from patients with IBD susceptibility alleles.
Cell death has been characterized in mouse small in-
testine epithelial organoids, and these ﬁnding may be
applied to studies of IBD.129 Future studies of organoid
models will facilitate the exploration of individual and
combinatorial contributions of Paneth cell and goblet cell
dysfunction, the gut microbiome, and cytokines to the
pathogenesis of IBD.Interactions Between GI Tissues and Microbes
Some microbes invariably result in GI disease, whereas
others only cause disease in susceptible individuals. Studies
of GI organoids might increase our understanding of sus-
ceptibility to and pathogenesis of microbial infections and
identify possible therapies. Gastric organoids have been
instrumental in these studies because they recapitulate in
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and recapitulate mechanisms of malignant transformation
secondary to infection.
In the stomach, histamine stimulates parietal cells to
secrete acid. Gastric epithelial organoids cocultured with
immortalized stomach mesenchymal cells reduced intra-
luminal pH in response to histamine; this effect was
reversed by the proton pump inhibitor omeprazole.137
Helicobacter pylori causes most cases of peptic ulcer dis-
ease by inducing hypersecretion of acid and has been
associated with gastric cancer. Proliferation increases in
PSC-derived gastric organoids infected with H pylori but not
with variants that lack its virulence factor, CagA.47
Injection of human gastric epithelial organoids with H
pylori leads to activation of nuclear factor kB (NF-kB), which
is also activated in gastric cancer cells, and expression of
the NF-kB target and neutrophil chemotactic factor, inter-
leukin-8.138 A separate study found activation of NF-kB and
upregulation of Sonic hedgehog, a protein involved in
vertebrate development, following injection of H pylori into
mouse gastric epithelial organoids.84 In another study,
Wroblewski et al extended in vivo studies139 by showing
that H pylori injection into mouse gastric epithelial orga-
noids disrupted barrier function by inducing mislocalization
of tight junction proteins.140 Similar to ﬁndings from PSC-
derived gastric organoids, this study also showed that
only H pylori variants expressing CagA increased prolifera-
tion in gastric organoids.139 Together, these studies have
shown that H pylori infection can be modeled in gastric
organoids and can be used to study potential mechanisms of
gastric transformation.
Intestinal organoids have also been used to study path-
ogens.131,141–144 Colonization of mouse small intestine
epithelial organoids with Salmonella enterica serovar
Typhimurium (referred to hereafter as Salmonella) reduced
their growth, disrupted tight junctions, activated inﬂam-
matory signaling via NF-kB, and reduced expression of
Lgr5.141 This study revealed the complexity of the response
to infection, even in the absence of immune cells.
Another study capitalized on the absence of immune
cells by studying the effect of a-defensins, which are anti-
microbial peptides produced in response to Salmonella
infection.142 Small intestine epithelial organoids made from
mice with wild-type or mutated a-defensins were injected
with Salmonella. Absence of mature a-defensin reduced
intraluminal bacterial killing, which could be partially
restored by expression of human a-defensin. This study
showed the contribution of a-defensins to the immune
response to Salmonella, which had been a challenge to
establish in vivo due to the commensal microbiota and the
cellular immune response in vivo.
Forbester et al showed that injection of Salmonella into
the lumen of human PSC-derived organoids resulted in
epithelial invasion, but this could be inhibited with injection
of a mutant strain of Salmonella with reduced invasive ca-
pacity.143 Researchers have also studied human PSC-derived
organoids infected with Clostridium difﬁcile, the leading
cause of health care–associated diarrhea.131 The obligate
anaerobe was able to survive up to 12 hours afterintraluminal injection, indicating low intraluminal oxygen
concentration despite ambient oxygen culture conditions.
Furthermore, puriﬁed toxin A and toxin B, determinants of C
difﬁcile virulence, also disrupted paracellular barrier func-
tion, whereas a nontoxigenic C difﬁcile strain did not. PSC-
derived intestinal organoids can therefore be used to
study anaerobic pathogen infections and possible
treatments.
GI organoids have been an indispensable tool for studies
of factors that contribute to complex and poorly understood
diseases such as necrotizing enterocolitis (NEC). NEC, which
affects premature, formula-fed infants, results in bowel ne-
crosis. Sodhi et al showed that lack of Toll-like receptor-4
(TLR4) protected neonatal mice from hypoxia-induced
NEC.145 Interestingly, small intestine epithelial organoids
generated from these mutant mice had increased goblet cell
differentiation. Administration of the Notch inhibitor
dibenzapine protected wild-type mice from NEC.
Another group observed an increase in p53 up-
regulated modulator of apoptosis (PUMA), which regu-
lates apoptosis, upon activation of TLR4.146 Activation of
TLR4 in mouse small intestine organoids also resulted in
reduced proliferation and increased apoptosis. However,
apoptosis was not observed in organoids that lacked
PUMA. Furthermore, PUMA was up-regulated in intestinal
crypts of mice and patients with NEC but not in TLR4-null
mice. The use of human neonatal epithelial organoids and
PSC-derived organoids to study the effects of microbes on
the intestinal epithelium in the presence and absence of
TLR4 signaling could increase our understanding of the
pathogenesis of NEC.
Viral pathogens have also been studied in gastrointes-
tinal organoids. Finkbeiner et al showed that clinical rota-
virus isolates can replicate within the epithelial and
mesenchymal cell compartments of PSC-derived intestinal
organoids.147 Epithelial and PSC-derived GI organoids can
therefore be used to study host-pathogen interactions and
develop new therapies for GI infections.
In addition to pathogens, GI organoids have been used to
understand the inﬂuence of indigenous (commensal) mi-
crobes on epithelial health. Stimulation of mouse small in-
testine crypts with muramyl dipeptide, a common bacterial
peptidoglycan motif, increased organoid formation.148 This
survival advantage was lost with deletion of NOD2, a re-
ceptor that directly senses bacterial products. Mice given
muramyl dipeptide before intestinal insult with doxorubicin
had increased crypt survival, and was not seen in NOD2-
knockout mice. Lukovac et al showed that the presence of
certain commensal bacteria led to expression of genes
involved in lipid metabolism in the intestinal epithelia.149
This model system may be used in the future to identify
bacteria that protect against obesity or IBD.Cancer
GI cancer organoids can model the pathophysiology of GI
malignancies and their response to treatment. Colonic
epithelial cells accumulate genetic changes that transform
them into adenocarcinomas, and intestinal organoids are
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noids generated from intestinal adenomas of APC-deﬁcient
mice, R-spondin-1 was not required to stimulate Wnt
signaling.60 Lentiviral knockdown of APC in mouse small
intestine epithelial organoids conﬁrmed Wnt activation and
perturbed differentiation; these organoids generated sub-
cutaneous tumors when injected into immunocompromised
mice.150 Activation of Kras in these organoids further
increased the tumor burden.150
APC loss of heterozygosity was also modeled using
epithelial organoids generated from the small intestine of
ApcMin/þ mice, a model of familial adenomatous polypo-
sis.151,152 Rad21 haploinsufﬁciency improved survival of
ApcMin/þ mice; and organoids from ApcMin/þ: Rad21þ/ mice
had reduced Apc loss of heterozygosity compared to orga-
noids from ApcMin/þ mice. A separate study showed that
treatment of murine epithelial organoids with TGF-b after
deletion of Apc increased apoptosis and levels of the pro-
apoptotic BH3-only protein BimEL isoform (Bim).153
Furthermore, a BH3 mimetic agent caused cell death in
primary colon adenocarcinoma organoids. Strikingly, mu-
tations in Kras, in conjunction with Apc deletion, delayed
apoptosis and decreased expression of Bim. Studies in in-
testinal organoids support the concept that loss of APC
contributes to colorectal carcinogenesis.
CRISPR-Cas9 genome editing has been used to mutate
tumor suppressor genes such as APC, SMAD4, and TP53, as
well as the oncogenes KRAS and PI3KCA, in colon epithelial
organoids grown from normal human colon tissues.154
Organoids in which all 5 genes were mutated grew inde-
pendent of growth factors and had gene expression signa-
tures similar to those of epithelial organoids generated from
human colon adenomas. Organoids containing the 5 muta-
tions formed tumors when transplanted into mice but with
lower frequency than colorectal adenocarcinoma organoids.
Transplantation of engineered and patient-derived colo-
rectal adenocarcinoma organoids under the kidney capsule
of immunocompromised mice resulted in tumor formation,
although patient-derived adenoma organoids did not
engraft.154 Organoids containing inactivating mutations of
APC, SMAD4, and TP53 and activating mutations in KRAS
also grew independently of growth factors and formed solid
tumors following subcutaneous injection into immunocom-
promised mice.155 In contrast, patient-derived control
organoids did not engraft after subcutaneous injection.
Epithelial organoids can therefore be used to assess the
combinatorial effects of mutations associated with
malignancy.
Consistent with studies linking mutations in the Wnt
signaling pathway to human colon adenocarcinoma, orga-
noids with high expression of the Wnt target gene, EphB2,
have a transcriptional signature similar to that of intestinal
stem cells and are more likely to form tumors following
subcutaneous injection into immunocompromised mice.156
Similarly, mouse small intestinal cells expressing high
levels of EPHB2 generated organoids more efﬁciently than
small intestinal cells with low expression of EPHB2.156
These data indicate that epithelial organoids can be used
to assess the proliferative capacity.Human colonic organoids generated from adenocarci-
nomas and adjacent normal tissues can be used to screen
potential therapeuticmolecules and identify drug sensitivities
in the setting of complex genetic interactions of the individual
patient. Engineered colon adenocarcinoma organoids with
TP53 loss of function mutations were associated with resis-
tance to the MDM2 inhibitor, nutlin-3a.155 Organoids from
colonic tumors with KRAS mutations were resistant to the
anti–epidermal growth factor receptor inhibitors cetuximab
and BIBW2992.157 GI organoids can therefore be used to
bridge pharmacological studies on short-term cultures and
xenotransplant studies to develop individualized treatment
regimens. Organoids might be used in high-throughput
screens of drugs and pharmacological agents for those with
effects in the patients from which organoids were generated.
Similar to organoids derived from epithelial tissues,
epithelial-mesenchymal organoids have been generated
from tumor samples.99,158 Li et al generated mouse colonic
epithelial-mesenchymal organoids with deletion of Apc,
activating mutations in Kras, and lentiviral knockdown of
p53 and SMAD4. Interestingly, the epithelial-mesenchymal
organoids generated from the small intestine were more
susceptible to transformation than organoids from the
colon. The small intestine organoids required alteration of
only 2 genes, whereas colon organoids required all 4
alterations for transformation.
Adenocarcinoma of the stomach is the second most
common cause of cancer worldwide, and patients have poor
prognoses.159 Given the poor response of gastric cancer to
treatment, there is a need to determine which patients are
most likely to respond to speciﬁc drugs. Mouse epithelial-
mesenchymal organoids from normal tissue have been
transformed into gastric cancer organoids through alter-
ations to Kras or p53.99 Gastric organoids with activating
mutations of Kras or loss of p53 become dysplastic and
generate adenocarcinomas in mice.99
Gastric epithelial organoids have been used to model
hereditary gastric cancer and determine the role of TGFB
receptor 2 (TGFBR2) in metastasis. Mutations in the cad-
herin 1 type 1 gene (CDH1 or ECAD) are associated with
hereditary gastric cancer. Nadauld et al performed genome
sequence analysis of a patient who developed gastric cancer
and later developed metastases. This study identiﬁed
alteration of TGFBR2 as a potential risk factor of metastatic
disease. Knockdown of TGFBR2 in mouse gastric epithelial
mesenchymal organoids with disruptions of Cdh1 and p53
increased tumorigeniciy when organoids were transplanted
in vivo.158 Thus, use of organoids conﬁrmed a suspected
tumor suppressor gene.
Whole-genome sequencing and epigenetic proﬁling of
gastric cancer and adjacent normal tissue specimens iden-
tiﬁed mutations in RHOA.160 Mouse intestinal epithelial
organoids with lentiviral overexpression of RHOA mutants
survived in the absence of the ROCK inhibitor, which pre-
vents anoikis after passage. RHOA mutations therefore seem
to promote survival and might contribute to gastric carci-
nogenesis. Studies of gastric organoids generated from pa-
tients’ tumors could provide more information about the
oncogenic effects of RHOA mutations.
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been generated by culture of primary cells from resected
gastric adenocarcinomas. Human gastric organoids derived
from normal and tumor tissues have similar morphologies
in culture. However, organoids derived from tumors engraft
within the gastric epithelium and generate metaplastic
phenotypes similar to the original patient tumor when
transplanted orthotopically into mice. (unpublished results,
Bertaux-Skeirik and Zavros, September 2015). This
approach might be used to develop an organoid-based
platform for testing the speciﬁc responses of individual
patients’ tumors to different therapeutic agents.
Epithelial organoids have also been generated from
Barrett’s esophagus (BE).60,160 BE predisposes esophageal
tissues to dysplasia and adenocarcinoma. BE can be identi-
ﬁed based on the presence of intestinal goblet cells.
Esophageal epithelial organoids generated from patients
with BE could be induced to undergo goblet cell differenti-
ation.60 Given recent developments in the ability to culture
mouse esophageal epithelial organoids, it might be possible
to develop normal human esophageal epithelial organoids,
which could be compared to BE or esophageal cancer
organoids.
Both epithelial organoids and tissue-derived epithelial
mesenchymal organoids have been used to model gastro-
intestinal malignancies. Colon cancer epithelial organoids
closely reﬂect primary tumor biology, are easily expandable,
and can be used in screens for drug efﬁcacy and toxicity.
Tissue epithelial-mesenchymal organoids also demonstrate
in vitro malignant progression. Future studies might use
epithelial-mesenchymal organoids and PSC-derived orga-
noids in screens of pharmacologic agents for activity against
gut tumors.Regenerative Medicine
Factors such as ease of culture, expandability, capacity to
model heterogeneous cell fates, and suitability to genetic
manipulation make GI organoids a useful tool. Long-term
organotypic cultures have been used to study the stem
cell niche and have recently been used as guides for normal
development and sources of replacement tissues. Genera-
tion of autologous tissue derived from biopsy specimens or
iPSCs offers advantages over conventional organ trans-
plants, which are limited in availability and require
immunosuppression.Endocrine Differentiation of Gut Organoids
GI endocrine cells secrete hormones; disruption of this
process can cause disease and death. For example, autoim-
mune destruction of insulin-producing pancreatic beta cells
results in type 1 diabetes mellitus, and loss of enter-
oendocrine cells leads to anendocrinosis and life-
threatening diarrhea.124,125 Dysregulation of gut hormones
has also been implicated in obesity and metabolic syn-
drome. Gut organoids can be used to study the pathogenesis
of these diseases and, perhaps more importantly, as an
alternative tissue source for therapeutics.161Ectopic expression of NGN3 or NEUROG3 in mouse
epithelial mesenchymal organoids, human PSC-derived in-
testinal organoids, and human PSC-derived gastric organo-
ids increased numbers of enteroendocrine cells, as it does in
mice.47,48,50,162–164 Furthermore, lentiviral knockdown of
ARX in PSC-derived intestinal organoids led to reduction of
cholecystokinin and secretin, similar to mice with intestine-
speciﬁc disruption of Arx.77 These studies conﬁrm the utility
of gut organoids in the study of enteroendocrine
differentiation.
PSC-derived intestinal organoids have also been used to
study transdifferentiation, or conversion from 1 cell lineage
into another, into insulin-producing cells.165,166 Bouchi
et al165 identiﬁed the transcription factor FOXO1 as a
marker of enteroendocrine cell progenitors and a regulator
of cell fate. Overexpression of a dominant-negative form of
FOXO1 increased insulin expression, indicating trans-
differentiation into insulin-producing cells. Ectopic expres-
sion of the dominant-negative form of FOXO1 also resulted
in upregulation of transcription factors important for the
development of insulin-producing pancreatic beta cells,
such as NEUROG3, MAFA, NEUROD1, and NKX6.1. Remark-
ably, expression of the dominant-negative form of
FOXO1 also resulted in secretion of C-peptide, a surrogate of
insulin secretion, in response to insulin secretagogues
such as glucose, arginine, and potassium chloride in vitro.
However, when these organoids were transplanted
subcutaneously into immunocompromised mice, human
C-peptide could not be detected in the mouse serum.
This result is likely due to low yield of insulin-producing
cells after FOXO1 inhibition (approximately 0.05% of cells in
the organoid).
In another study showing that PSC-derived intestinal
organoids can be transdifferentiated into insulin-producing
cells, lentivirus was used to ectopically express transcrip-
tion factors necessary for pancreatic beta-cell development,
Pdx1, MAFA, and Ngn3 (PMN).166 PMN-expressing organoids
produced insulin messenger RNA and protein. Moreover,
22% of cells produced C-peptide, indicating that over-
expression of PMN results in more efﬁcient generation of
insulin-producing cells than inhibition of FOXO1. It is not
clear whether PMN-expressing organoids can reduce fea-
tures of diabetes in animal models.
Bouchi et al also conﬁrmed the presence of enter-
oendocrine cells in PSC-derived organoids that produce
glucagon-like peptide 1, gastric inhibitory polypeptide,
somatostatin, ghrelin, and cholecystokinin. As such, PSC-
derived organoids can be used to study regulators of
hormone secretion and the effects of hormone secretion on
other tissue types in vitro and in vivo. PSC-derived orga-
noids might also be used in bariatric surgery research.
Weight loss after bariatric surgery does not occur via
reduction of enteric surface area or carrying capacity, but
rather via biochemical changes.167 PSC-derived organoids,
which are transplanted in discontinuity with the gut, permit
delineation of enteroendocrine hormone production due to
enteral content versus changes due to biochemical modu-
lators. They might be used to identify biochemicals that
obviate the need for bariatric surgery.
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Short bowel syndrome occurs when a signiﬁcant length
of small bowel is resected due to congenital anomalies,
infection or inﬂammation, or intestinal ischemia. As a result,
patients fail to maintain ﬂuid, electrolyte, or nutrient
homeostasis. Supportive therapy, including parenteral
nutrition, and curative therapy, such as small bowel trans-
plantation, cause complications with signiﬁcant morbidity
and mortality. Therefore, alternative ways to extend existing
bowel length, or new methods to replace missing tissue are
needed.168
Each of the 3 types of gut organoids have been suc-
cessfully transplanted into mice, and thus, might be used to
engineer small intestine.54,57,82,99,113,117 Mice with DSS-
induced colitis that were given enemas containing epithe-
lial colon organoids had higher body weights 2 weeks after
transplantation than mice that did not receive the organoids.
The organoids engrafted and were functional 4 weeks after
transplant.54 Similarly, mouse fetal and adult small intestine
epithelial organoids engrafted into the distal colon after
induction of inﬂammation.57,113
Orthotopic transplantation of mouse intestinal orga-
noid tissue has required induction of inﬂammation. Hu-
man epithelial organoids transplanted under the kidney
capsule or subcutaneously do not engraft in the absence of
transforming mutations.153,154 In contrast, human PSC-
derived intestinal organoids have been transplanted un-
der the kidney capsule or in the omentum without the use
of inﬂammatory agents such as DSS.82,117 Additional
studies are necessary to determine if human epithelial
organoids can engraft in the colon in the presence of
inﬂammation as this might be a new therapeutic approach
for IBD.127
Intestinal organoids have not yet been used to lengthen
small intestine. Most bowel-lengthening studies use orga-
noid units, generated from fragments of full-thickness
jejunum or ileum. These contain a mesenchymal core sur-
rounded by a polarized intestinal epithelium. After being
loaded onto polymer scaffolds, organoid units were ﬁrst
successfully transplanted into the omentum of syngeneic
Lewis rats to create tissue-engineered small intestine
(TESI).169 TESI have been appended to the anastomosis in
rat models of small bowel resection.170 Interestingly, in-
clusion of TESI in the anastomosis increased bowel length 9
months after bowel reconstruction and caused faster weight
gain after reconstruction.170,171
TESI has also been generated from human small intes-
tinal tissue and successfully transplanted into immuno-
compromised mice.168 The major limitation of this
approach, however, is the undetermined ability to expand
TESI long-term in vitro. In contrast, reconstituted epithelial-
mesenchymal organoids, epithelial organoids, and PSC-
derived organoids can all be expanded in vitro. A recent
study demonstrated that human PSC-derived intestinal
organoids seeded on PGA/PLLA scaffolds thrive after
transplantation in mice.172 More studies are needed to
determine whether these approaches can be used to in-
crease bowel length. Reconstituted epithelial-mesenchymalorganoids and PSC-derived organoids are likely to be
effective because of their mesenchymal support structure.
However, synthetic scaffolds could provide the necessary
support for transplanted epithelial organoids.Limitations
Despite the strengths that organoids offer over tradi-
tional cell lines, their use is restricted. For example,
although organoids are complex and often retain multiple
cell lineages, they lack many of the cellular inputs present in
an in vivo system (eg, neural, endothelial, or immune cells).
Complexity can be increased through coculture with addi-
tional cell types, but organoids should still be viewed as a
reductionist system.
Organoids are also limited by signiﬁcant variations
among laboratories in methods and tissue sources. This
issue is less of a concern with PSC-derived organoids,
because laboratories generally access the same cell lines and
follow well-established methods to differentiate organoids.
Conversely, tissue-derived organoids are generated from
patients using growth methods that have been optimized in
each laboratory. This heterogeneity affects reproducibility if
the derivation and characterization of the lines are not well
described. For example, changing growth conditions for
tissue-derived intestinal epithelial organoids can skew the
differentiation state from stem cell enriched to a balance of
stem cells and differentiated cell types.
A practical limitation of organoid models is their cost of
maintenance. Many commercial growth factors that are
required for culture; these can be expensive and have poor
bioactivity. These limitations also restrict assays that
require signiﬁcant scale-up, such as drug screens, providing
barriers to their use in personalized medicine approaches.
Many groups have turned to cell lines that generate growth
factors in conditioned media to reduce costs and improve
bioactivity, but this introduces additional experimental
variation.Future Directions
Organoid cultures have been developed for multiple GI
organs. These systems are multicellular, similar to in vivo
models, but have the ﬂexibility of in vitro systems. As such,
gut organoids have become a powerful tool with steadily
increasing applications.
Intestinal organoid cultures continue to offer insights
into the stem cell niche. Researchers have recently begun
to focus on generating patient-speciﬁc tissues. Individual-
ized organoids can be used to identify intestine-speciﬁc
pathophysiologies in complex disease processes, such as
lack of forskolin-induced swelling in organoids with
mutated CFTR. Patient-speciﬁc organoids can be used to
study mechanisms of diseases such as MVID and MIA.
Organoids generated from normal and tumor specimens
can be used to characterize the events that occur during
transformation, growth, and progression of malignancies
such as colorectal or gastric cancers. Organoids generated
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tinal tissues for patients with disorders such as short
bowel syndrome or IBD and avoid the adverse effects of
immune rejection or immune suppression. Finally, orga-
noids can be used in screens of pharmacological agents that
have effects on cells and tissues from individual patients to
advance personalized medicine.References
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